title: The effects of nodakenin on airway inflammation, hyper-responsiveness and remodeling in a murine model of allergic asthma.
abstract: BACKGROUND
  Nodakenin is a major coumarin glucoside in the root of Peucedanum decursivum Maxim, a commonly used traditional Chinese medicine for the treatment of asthma and chronic bronchitis for thousands of years.
  
  
  OBJECTIVE
  In this work, the anti-asthma potential of nodakenin was studied by investigation of its effect to suppress airway inflammation, hyper-responsiveness and remodeling in a murine model of chronic asthma.
  
  
  METHODS
  BALB/c mice sensitized to ovalbumin (OVA) were challenged with aerosolized OVA for 8 weeks, orally administered with nodakenin at doses of 5, 10 and 20 mg/kg before each OVA challenge.
  
  
  RESULTS
  Compared with the model group, nodakenin treatment markedly inhibited airway inflammation, hyper-responsiveness and remodeling, showing improvement in subepithelial fibrosis, smooth muscle hypertrophy, and goblet cell hyperplasia, and decreased levels of interleukin (IL)-4, IL-5, IL-13 and matrix metalloproteinase-2/-9 in bronchoalveolar lavage fluid, and the level of OVA-specific IgE in serum. In addition, the NF-κB DNA-binding activity in lung tissues was also reduced by nodakenin treatment.
  
  
  CONCLUSIONS
  These data indicated that nodakenin might mitigate the development of chronic experimental allergic asthma.
authors.affiliation: College of Food and Drug, Anhui Science and Technology University , Fengyang, Anhui , People's Republic of China and.
authors.forename: Youyi
authors.initials: Y
authors.lastname: Xiong
authors.forename: Junsong
authors.initials: J
authors.lastname: Wang
authors.forename: Hao
authors.initials: H
authors.lastname: Yu
authors.forename: Xiaolin
authors.initials: X
authors.lastname: Zhang
authors.forename: Chenggui
authors.initials: C
authors.lastname: Miao
authors.forename: Shitang
authors.initials: S
authors.lastname: Ma
mesh_terms: D000818:Animals; D018927:Anti-Asthmatic Agents / Q000627:therapeutic use*; D001249:Asthma / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D016535:Bronchial Hyperreactivity / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D001991:Bronchitis / Q000188:drug therapy* / Q000473:pathology; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D003374:Coumarins / Q000627:therapeutic use*; D016207:Cytokines / Q000378:metabolism; D005260:Female; D005960:Glucosides / Q000627:therapeutic use*; D006967:Hypersensitivity / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D007958:Leukocyte Count; D051379:Mice; D008807:Mice, Inbred BALB C; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D016328:NF-kappa B / Q000187:drug effects
chemical_list: D018927:Anti-Asthmatic Agents; D003374:Coumarins; D016207:Cytokines; D005960:Glucosides; D016328:NF-kappa B; D020928:Mitogen-Activated Protein Kinases; C471579:nodakenin
keywords: Airway hyper-responsiveness; airway inflammation; airway remodeling; asthma; nodakenin